Racial And Ethnic Diversity In Clinical Trials: A Social And Scientific Imperative

From new FDA guidance and community engagement efforts to the challenges of precision medicine and decentralization, In Vivo spoke with industry experts about racial and ethnic diversity in the context of clinical trials.

Diversity
• Source: Shutterstock

On average, 20% of drugs approved each year have different response rates depending on a patient’s race or ethnicity. Enrolling a diverse patient population in clinical trials allows industry to identify differences in efficacy and safety across different sub-populations which in turn facilitates the delivery of effective drugs for all, Pfizer Inc.’s head of clinical trial experience Judy Sewards told In Vivo.

A spokesperson from Bristol Myers Squibb Company concurred and told In Vivo that “diversity in clinical trials is both...

More from Outlook Archive

Big Three Lead From The Front With Medtech Back On Solid Growth Footing

 
• By 

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.  

Infographic: Top 100 Pharma Companies

 

The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.    

Pfizer Leads An Unusual Year For The Scrip 100

 

Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.      

Outlook 2023: The Pharma Rollercoaster Shows No Signs Of Slowing Down

 
• By 

What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.

More from Outlook